Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $148000.0.

  • Niagen Bioscience's Cash from Financing Activities fell 8575.55% to $148000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year increase of 59540.45%. This contributed to the annual value of $5.4 million for FY2024, which is 606555.56% up from last year.
  • Niagen Bioscience's Cash from Financing Activities amounted to $148000.0 in Q3 2025, which was down 8575.55% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Cash from Financing Activities registered a high of $33.4 million during Q1 2021, and its lowest value of -$76000.0 during Q4 2023.
  • Its 5-year average for Cash from Financing Activities is $2.9 million, with a median of $148000.0 in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 9029189.19% in 2021, then plummeted by 130000.0% in 2024.
  • Niagen Bioscience's Cash from Financing Activities (Quarter) stood at $63000.0 in 2021, then skyrocketed by 12088.89% to $7.7 million in 2022, then plummeted by 100.99% to -$76000.0 in 2023, then surged by 5031.58% to $3.7 million in 2024, then plummeted by 96.05% to $148000.0 in 2025.
  • Its Cash from Financing Activities was $148000.0 in Q3 2025, compared to $3.7 million in Q2 2025 and $3.1 million in Q1 2025.